Research programme: leishmaniasis therapies - WHO/Tibotec

Drug Profile

Research programme: leishmaniasis therapies - WHO/Tibotec

Alternative Names: Leishmaniasis therapies research programme - WHO/Tibotec; PX 6518; Research programme: saponins - WHO/Tibotec; Saponins research programme - WHO/Tibotec

Latest Information Update: 16 Jul 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator World Health Organization
  • Developer Janssen Infectious Diseases BVBA
  • Class Triterpenes
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Visceral leishmaniasis

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Visceral-leishmaniasis in Belgium
  • 20 Feb 2008 No development reported - Preclinical for Visceral leishmaniasis in Belgium (unspecified route)
  • 10 Mar 2004 Preclinical trials in Visceral leishmaniasis in Belgium (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top